Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00308243|
Recruitment Status : Completed
First Posted : March 29, 2006
Last Update Posted : July 19, 2011
|Condition or disease||Intervention/treatment||Phase|
|Cystic Fibrosis||Drug: Sodium Pyruvate in 0.9% Sodium Chloride Solution||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis. A Phase I, Double Blind, Placebo Controlled, Safety Study. Stage 1)|
|Study Start Date :||March 2006|
|Actual Primary Completion Date :||March 2007|
|Actual Study Completion Date :||March 2007|
- The primary outcome variable is the assessment of safety of inhaled sodium pyruvate in subjects with CF.
- The secondary outcome variable is the determination of improvement in lungs of CF subjects as determined by measurement of FEV1 and/or as determined by measurement of reduced inflammatory markers in induced sputum.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00308243
|United States, Minnesota|
|University of Minnesota Medical School, The Minnesota Cystic Fibrosis Center|
|Minneapolis, Minnesota, United States, 55455|
|Study Director:||Joanne Billings, MD||University of Minnesota; Pulmonary, Allergy & Critical Care Medicine|